Menu Search
Equities

NovaBay Pharmaceuticals Inc

B9P0:MUN

NovaBay Pharmaceuticals Inc

Actions
  • Price (EUR)0.788
  • Today's Change0.352 / 80.53%
  • Shares traded4.00k
  • 1 Year change-94.91%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 20:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year NovaBay Pharmaceuticals Inc had relatively flat revenues (14.40m to 14.73m), though the company grew net income from a loss of 10.61m to a smaller loss of 9.64m. A reduction in the selling, general and administrative costs as a percentage of sales from 106.13% to 87.12% was a component in the net income growth despite flat revenues.
Gross margin58.55%
Net profit margin-87.67%
Operating margin-66.51%
Return on assets-105.75%
Return on equity-549.55%
Return on investment-205.52%
More ▼

Cash flow in USDView more

In 2023, cash reserves at NovaBay Pharmaceuticals Inc fell by 2.24m. Cash Flow from Financing totalled 1.91m or 12.97% of revenues. In addition the company used 4.13m for operations while cash used for investing totalled 19.00k.
Cash flow per share-28.94
Price/Cash flow per share--
Book value per share-0.4577
Tangible book value per share-0.4577
More ▼

Balance sheet in USDView more

NovaBay Pharmaceuticals Inc has a Debt to Total Capital ratio of 881.01%.
Current ratio0.6241
Quick ratio0.4302
Total debt/total equity--
Total debt/total capital8.81
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.